pharmaphorum
MARCH 31, 2022
University College Dublin spinout Kinesis Health Technologies, which has developed a range of wearable sensors to assess the physical capabilities of patients, has been bought by US company Linus Health for an undisclosed sum. The merger brings together Kinesis’ gait analysis tools with Linus’ digital brain health monitoring technologies, designed to spot diseases like Alzheimer’s before over symptoms develop.
Outsourcing Pharma
MARCH 31, 2022
A renowned university researcher explains the path that laid the foundation and what the novel diagnostic and treatment means for prostate cancer patients.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
MARCH 31, 2022
Leading tennis players train two to three hours a day to prepare for tournaments and have daily coaching input to make them game ready. It’s a gruelling regime but the rewards are obvious. Competing at the top level in pharma sales could be developed by following in the fast footsteps of Roger Federer and Rafael Nadal. Experts believe time spent practising delivery and messaging will reap dividends providing it is grooved into a sales force or medical science liaison (MSL) team’s schedule.
Pharma Mirror
MARCH 31, 2022
It all started in March 2020 and it is now Jan 2022. We still can’t declare the COVID pandemic as “finished”. How has the pandemic impacted the field marketing activity of Pharma companies? What should the industry do to prepare for what will definitely be a new world, post-COVID? There were many analysts who, even before the pandemic, were saying that the role of Medical Representatives will reduce.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
pharmaphorum
MARCH 31, 2022
Is engagement the equivalent of a “digital smile” in pharma marketing, or have we been measuring communications efficacy all wrong? The way pharma communicates with healthcare professionals (HCPs) has transformed in recent years, with field force visits fast being replaced – at least in part – by digital communications. It’s a shift that has challenged marketeers and medical teams alike to learn the metrics that drive sales success in a content-driven world.
Pharma Mirror
MARCH 31, 2022
The leading European pharmaceutical marketplace now hosts more than 85 000 CTD dossiers for finished dosage formulation products. Compared to 19 600 products at the start of 2021, the product offering has increased fourfold over a single year. As a response to increasing demand, Pipelinepharma will introduce biosimilar drugs into a separate category.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharma Mirror
MARCH 31, 2022
Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of pharmaceuticals, vaccines and biopharmaceuticals including Advanced Therapeutical Medicinal Products (ATMPs), has announced the completion of a £1.3 million collaborative UKRI-funded project as part of the medicines manufacturing challenge.
pharmaphorum
MARCH 31, 2022
More than 250,000 people living with type 1 diabetes in the UK will be offered real-time continuous glucose monitoring (CGM) technology, reducing their reliance on fingerprick testing, according to NICE. Finalised guidance from the health technology assessment (HTA) agency recommends real-time CGM for all children and adults with type 1 diabetes for the first time, helping them to manage their condition.
Outsourcing Pharma
MARCH 31, 2022
An expert from the clinical technology solutions provider discusses some of the top challenges associated with technology adoption, and how to tackle them.
pharmaphorum
MARCH 31, 2022
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson’s disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech said today that the orally-active GPR6 inverse agonist reduced the time people with Parkinson’s experienced so-called ‘off’ episodes, when symptoms of the illness re-emerge despite treatment with dopaminergic drugs like L-DOPA.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
MARCH 31, 2022
In phase 2 trials, the drug reduced ‘OFF time’ which refers to periods of the day when Parkinson’s symptoms recur despite medication
pharmaphorum
MARCH 31, 2022
The board of Eikon Therapeutics will soon look like Merck & Co’s a few years ago – after the big pharma’s former CEO Ken Frazier agree to join his former colleagues Roger Perlmutter and Roy Baynes at the startup. Eikon CEO Perlmutter – who was head of R&D at Merck for nine years – said Frazier would be joining the biotech as its first independent board member, adding that the company “will benefit enormously from Ken’s deep knowledge of the pharmaceutical industry
Pharma Times
MARCH 31, 2022
MTX652 has advanced through preclinical regulatory toxicology studies and is ready for a phase 1 trial
pharmaphorum
MARCH 31, 2022
UK startup Sano Genetics has raised $11 million in first-round financing to develop its go-between service, which aims to overcome one of the big challenges in clinical research by connecting patients with trial sponsors. The Cambridge-based company said the new funding – which adds to around $4 million in seed financing – will be used to grow its team in the US and Europe, and develop its platform to cover more than 50 disease categories in at least six countries by the middle of next year.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
pharmaphorum
MARCH 31, 2022
By a narrow margin, an FDA advisory committee has voted against approval of Amylyx’ experimental medicine for amyotrophic lateral sclerosis until the company can provide more evidence that it is effective. The prospects of a positive vote on AMX0035 (sodium phenylbutyrate and taurursodiol) were looking dim after the FDA expressed its doubts about the efficacy data in Amylyx’ single 140-subject study, although the desperate need for new treatments for ALS had the company hopeful it ha
Expert insights. Personalized for you.
105 
Let's personalize your content